Dexmedetomidine sublingual film
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Delirium
Conditions
Delirium
Trial Timeline
Jun 1, 2020 → Jun 1, 2021
NCT ID
NCT04382170About Dexmedetomidine sublingual film
Dexmedetomidine sublingual film is a phase 2 stage product being developed by BioXcel Therapeutics for Delirium. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04382170. Target conditions include Delirium.
What happened to similar drugs?
5 of 13 similar drugs in Delirium were approved
Approved (5) Terminated (3) Active (6)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04382170 | Phase 2 | Withdrawn |
Competing Products
17 competing products in Delirium
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lemborexant 5 mg + Control (placebo) group | Eisai | Phase 2 | 42 |
| Suvorexant + Placebo | Merck | Phase 3 | 40 |
| Suvorexant 20 mg + Placebo | Merck | Phase 2 | 35 |
| Rivastigmine + Placebo | Novartis | Approved | 35 |
| Rivastigmine prevention of delirium | Novartis | Phase 3 | 40 |
| Rivastigmine transdermal patch + placebo patch | Novartis | Phase 3 | 40 |
| Rivastigmine Patch | Novartis | Approved | 43 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 32 |
| Parecoxib | Pfizer | Approved | 39 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 32 |
| Pregabalin | Pfizer | Phase 3 | 40 |
| Dexmedetomidine + Midazolam | Pfizer | Phase 3 | 47 |
| Propofol + Dexmedetomidine | Pfizer | Pre-clinical | 26 |
| Dexmedetomidine + Saline placebo | Pfizer | Phase 2/3 | 38 |
| Cyclopofol + Propofol | Haisco Pharmaceutical Group | Approved | 39 |
| Dexmedetomidine + Sodium chloride 0.9% | Baxter | Phase 3 | 37 |
| Dexmedetomidine Hydrochloride Group | Brain Biotech | Approved | 40 |